Smith & Nephew stock costs EUR 13.00 before November 4 results
Published on 10/20/2026 at 13:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDebt and reporting dates
- Smith & Nephew announced a USD 350 million note redemption on October 1, 2026.
- Analysts forecast USD 1,552 million in third-quarter revenue for 2026, with 3.3 percent underlying growth.
- Smith & Nephew stock was trading at EUR 13.00 at 1:15 p.m. CEST at Lang & Schwarz on October 20, 2026.
Smith & Nephew stock was trading at EUR 13.00 at Lang & Schwarz on October 20, 2026 at 1:15 p.m. CEST, with third-quarter results scheduled for November 4, 2026. The company also announced on October 1, 2026 that it would redeem USD 350 million of notes due in 2027, according to The Globe and Mail.
Debt redemption sets context
The notes carry a 5.150 percent coupon and are scheduled for repayment at 100.245 percent of principal, plus accrued interest, under the terms reported by The Globe and Mail. The move removes a near-term maturity from the capital structure, while the upcoming trading report will provide the next operating test.
What does November 4 bring?
Smith+Nephew will publish its third-quarter 2026 results on November 4, 2026. Its analyst consensus dated October 2, 2026 covers 14 analysts and puts average third-quarter revenue at USD 1,552 million, with 3.3 percent underlying growth.
Three dated company milestones
On August 4, 2026, Smith+Nephew published its second-quarter and first-half results. On September 22, 2026, it announced FDA 510(k) clearance and the first surgical case for its LANDMARK Total Knee System. On October 1, 2026, it announced the USD 350 million note redemption.
Next company date
The next substantiated company date is November 4, 2026, for the third-quarter trading report, as listed on the investor-relations page.
Stock price and reporting test
The market price gives investors a dated reference ahead of the report, while the consensus sets a measurable bar for revenue and underlying growth. Smith & Nephew operates across Advanced Wound Management, Sports Medicine and ENT, and Orthopaedics, and its shares are traded in London and New York.
The further course of trading is shown by the continuously updated real-time quote of Smith and Nephew stock.
Smith & Nephew at a glance
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- Ticker: SN.L
- Primary exchange: London Stock Exchange
- Price Lang & Schwarz (as of October 20, 2026, 1:15 p.m. CEST): EUR 13.00
- Sector / Industry: Health care / Medical technology
- Index membership: FTSE 100
Market context: Market report FTSE 100.
